Edition:
United Kingdom

ContraFect Corp (CFRX.OQ)

CFRX.OQ on NASDAQ Stock Exchange Capital Market

0.92USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$0.92
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
20,433
52-wk High
$2.50
52-wk Low
$0.80

Summary

Name Age Since Current Position

Steven Gilman

64 2017 Chairman of the Board, Chief Executive Officer

Joshua Muntner

48 2017 Co-Chief Executive Officer, Senior Vice President - Business Development

Michael Messinger

42 2017 Co-Chief Executive Officer, Vice President - Finance

Roger Pomerantz

60 2014 Vice Chairman of the Board

Lisa Ricciardi

56 2017 Chief Operating Officer, Director

Nancy Dong

2014 Vice President, Controller

Cara Cassino

55 2017 General Counsel, Secretary, Chief Medical Officer

Natalie Bogdanos

46 2014 General Counsel and Corporate secratary

Sol Barer

69 2015 Lead Independent Director

Isaac Blech

67 2010 Independent Director

David Low

56 2014 Independent Director

Michael Otto

66 2014 Independent Director

David Scheinberg

61 2010 Independent Director

Cary Sucoff

64 2010 Independent Director

Biographies

Name Description

Steven Gilman

Dr. Steven C. Gilman, PhD., is Chairman of the Board, Chief Executive Officer of the Company, Dr. Gilman has served as the Company’s Interim Chief Executive Officer since March 21, 2016, and as Chairman of the Board since May 2015. Until 2015, he served as the Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals, a biopharmaceutical company, until its acquisition by Merck & Co. Prior to joining Cubist in 2008, he served as Chairman of the Board of Directors and Chief Executive Officer of ActivBiotics, a privately held antibacterials company. Previously, he worked at Millennium Pharmaceuticals, Inc., where he held a number of senior leadership roles including Vice President and General Manager of the Inflammation franchise. Dr. Gilman currently serves on the board of directors of publicly traded companies Keryx Biopharmaceuticals, Inc., Momenta Pharmaceuticals, Inc., Vericel Corporation and SCYNEXIS Inc. The Company believes that Dr. Gilman’s significant scientific, executive and board leadership experience in the pharmaceutical and biotechnology industries qualifies him to serve as a member of the Board.

Joshua Muntner

Mr. Joshua B. Muntner is Co-Chief Executive Officer, Senior Vice President - Business Development of ContraFect Corporation. He brings over 15 years of healthcare investment banking experience to ContraFect, and has been involved with a wide range of capital markets and advisory transactions with approximately USD 11bn in value. Most recently, Mr. Muntner was a Managing Director and Co-Head of Healthcare Investment Banking at Janney Montgomery Scott, where he was responsible for originating and executing equity financing and M&A transactions for the firm’s life science clients. Prior to Janney, Mr. Muntner served as Managing Director at ThinkEquity, where he re-established the firm’s healthcare banking practice. Mr. Muntner spent nine years at Oppenheimer & Co. and its predecessor, CIBC World Markets, after starting his investment banking career at Prudential Securities. Mr. Muntner received his MBA from the UCLA Anderson School of Management and a Bachelor of Fine Arts from Carnegie Mellon University.

Michael Messinger

Mr. Michael Messinger, CPA is Co-Chief Executive Officer, Vice President - Finance of the company. Mr. Messinger has more than 15 years of experience in finance, accounting and forecasting for clinical development. He served as Controller of Coelacanth Corporation prior to his role as Director of Finance for Lexicon Pharmaceuticals, Inc. In this capacity, he was responsible for the financial management of Lexicon's partnership with Symphony Capital, LLC, in addition to coordinating fiscal and program management concerning Lexicon's development programs. Mr. Messinger received his B.B.A degree in accounting from the University of Michigan. He started his career as an auditor at Ernst & Young, LLP.

Roger Pomerantz

Dr. Roger J. Pomerantz, M.D. is a Vice Chairman of the Board of CONTRAFECT CORPORATION,, Previously, Dr. Pomerantz was Worldwide Head of Licensing & Acquisitions, Senior Vice President at Merck & Co., Inc. where he oversaw all licensing and acquisitions at Merck Research Laboratories. Previously, he served as Senior Vice President and Global Franchise Head of Infectious Diseases at Merck. Prior to joining Merck, Dr. Pomerantz was Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals. He joined Johnson & Johnson in 2005 as President of Tibotec Pharmaceuticals, Inc. Dr. Pomerantz currently serves as the Chairman of the Board of Directors for Seres Health Inc. Dr. Pomerantz received his B.A. in Biochemistry at the Johns Hopkins University and his M.D. at the Johns Hopkins School of Medicine. He received post-graduate training at the Massachusetts General Hospital, Harvard Medical School and M.I.T. Dr. Pomerantz is Board Certified in both Internal Medicine and Infectious Diseases.

Lisa Ricciardi

Ms. Lisa R. Ricciardi serves as Chief Operating Officer, Director of the Company. Ms. Ricciardi is a Life Sciences executive with deep business development and operational experience. She has worked for top pharmaceutical, payer, and molecular diagnostics firms including Pfizer, Inc., Medco Health Solutions, Inc., and Foundation Medicine, as well as for Essex Woodlands Health Ventures, a global venture capital partnership. She currently serves on the board of Chimerix, Inc, and United Drug Healthcare Group, PLC, and was a prior board member of Sepracor Inc., which was sold to Dainippon Sumitomo for $2.6 billion.

Nancy Dong

Nancy Dong is Vice President, Controller of Company. Ms. Dong has more than 20 years of experience in accounting, strategic planning, budgeting and forecasting, organizational development, financial systems and controls. She served as controller at XL Marketing and Alley Corp prior to her role as Vice President of Finance and Administration at DCM, a tele-services firm supporting the performing arts. Ms. Dong also held the positions of COO/CFO at Semaphore, a project management software development firm. Ms. Dong received her B.A. degree from Yale University and a MPPM degree from The Wharton School at the University of Pennsylvania. She started her career as a management consultant at Ernst & Young.

Cara Cassino

Dr. Cara Cassino M.D., is General Counsel, Secretary, Chief Medical Officer of the Company., effective 25 September 2015. She has extensive experience in the design and execution of drug development programs across a broad range of therapeutic areas, and has led more than 20 regulatory submissions that resulted in approvals in the United States and abroad. Dr. Cassino was previously Senior Vice President, Global Clinical Development at Forest Laboratories, Inc. (“Forest”) where she served as a member of Forest’s R&D Executive Leadership team and was responsible for the clinical development of a portfolio of over 35 compounds, (including 7 drugs in the anti-infective space) and was also instrumental in the clinical due diligence process for Forest’s $2.9 billion acquisition of Aptalis Pharma and $1.1 billion acquisition of Furiex Pharmaceuticals. Prior to joining Forest, Dr. Cassino held a number of senior executive positions at Pfizer Inc. (“Pfizer”), including Global Medical Team Leader of Pfizer’s antibacterial franchise and also Medicines Development Group Vice President for Pulmonary Vascular Disease and Rare Disease. Prior to joining Pfizer, Dr. Cassino held positions of increasing responsibility at Boehringer Ingelheim GmbH (“Boehringer”), culminating in the role of Executive Medical Director of Boehringer’s late stage respiratory franchise in the U.S. Prior to joining Boehringer, Dr. Cassino was a member of the academic faculty of the Division of Pulmonary and Critical Care Medicine at the New York University (“NYU”) School of Medicine. Dr. Cassino received both her medical degree, and B.A. in Chemistry and Fine Arts, summa cum laude and Phi Beta Kappa, from NYU. Dr. Cassino completed her internship and residency in Internal Medicine at NYU/Bellevue Hospital, followed by fellowship in Pulmonary/Critical Care Medicine at NYU and Mount Sinai Medical Center in New York City.

Natalie Bogdanos

Ms. Natalie Bogdanos, Esq. has been appointed as General Counsel of ContraFect Corporation., effective as of August 18, 2014. Prior to joining ContraFect, Ms. Bogdanos served as Associate General Counsel at Memorial Sloan-Kettering Cancer Center (MSKCC) where she held a joint appointment with the Office of the General Counsel and the Office of Technology Development (OTD). At MSKCC, she provided legal counsel and guidance to various departments throughout the institution while having sole responsibility for the legal oversight of the OTD. She led the contracts group, managed the institution’s patent portfolio, provided regulatory guidance and compliance, and advised on litigation strategy. Prior to MSKCC, she was General Counsel at Enzo Biochem, Inc. (Enzo), a publicly-traded biotechnology company, from 2003 to 2012. At Enzo, she was responsible for leading the legal department, handling contracts and complex business development agreements, ensuring SEC and regulatory compliance, overseeing litigation and managing Enzo’s portfolio of 500+ patents and patent applications. Ms. Bogdanos has also served as a legal consultant to pharmaceutical companies and is presently a faculty member at the Practising Law Institute. Prior to attending law school, she was a research technician at the Public Health Research Institute where her work focused on Staphylococcus aureus. Ms. Bogdanos is an attorney licensed to practice before the United States Patent and Trademark Office. She is admitted to practice law in New York, the United States District Court, Southern and Eastern District of New York and the United States Court of Appeals for the Federal Circuit. Ms. Bogdanos received her Juris Doctor from New York Law School and her Bachelor of Arts in Biology, with honors, from Queens College of the City University of New York.

Sol Barer

Dr. Sol J. Barer, Ph.D. is Lead Independent Director of the Company. He was an Chairman of the Board of Company. Dr. Barer is the Managing Director of SJ Barer Consulting, LLC. He served as Chairman of Celgene Corporation (“Celgene”) from January 2011 to June 2011 and as Executive Chairman from June 2010 to January 2011. Prior to that time, he served as Chief Executive Officer of Celgene from January 2006 to June 2010, as Chairman from January 2007 to June 2010, as President in 1993 and Chief Operating Officer and director in 1994. He previously served as Senior Vice President, Science and Technology, and Vice President/General Manager, Chiral Products, from 1991 to 1994, and Vice President, Technology, from 1987 to 1991. Dr. Barer serves on the boards of directors of Aegerion Pharmaceuticals, Inc., Amicus Therapeutics, Cerecor Inc. (Chair), InspireMD Inc. (Chair), Centrexion (Chair), Restor Genex (Chair) and Medgenics Inc. (Chair). He has previously served as Commissioner of the New Jersey Commission on Science and Technology and as Chairman of the University of Medicine and Dentistry of New Jersey Governor’s Advisory Committee. Dr. Barer received a Ph.D. in organic chemistry from Rutgers University. We believe that Dr. Barer’s significant scientific, executive and board leadership experience in the pharmaceutical industry qualifies him to serve as a member of our board of directors.

Isaac Blech

Mr. Isaac Blech is a Independent Director of CONTRAFECT CORPORATION.,. Mr. Blech is a renowned biotechnology entrepreneur and investor, who, over the past 32 years, has founded and served on the boards of a number of companies which have produced major advances in a broad array of diseases, including the diagnosis of chlamydia, herpes, syphilis and HIV, and the treatment of cystic fibrosis, sexual dysfunction, multiple myeloma and brain cancer. The companies he founded include Celgene Corporation, ICOS Corporation, Nova Pharmaceutical Corporation, Pathogenesis Corporation and Genetics Systems Corporation. Mr. Blech is a major shareholder and Vice Chairman of Cerecor, Inc., and major shareholder and Vice Chairman of Edge Therapeutics. He is also a major shareholder and Vice Chairman of The SpendSmart Payments Company as well as a major shareholder and Vice Chairman of Premier Alliance Group. Mr. Blech is a director of Medgenics, Inc. Mr. Blech earned a B.A. degree from Baruch College in 1975.

David Low

Mr. David N. Low is a Independent Director of CONTRAFECT CORPORATION,, Mr. Low has worked as an investment banker since 1987, with broad investment and advisory experience in the life sciences, biotechnology and medical technology sectors. Since 2002, Mr. Low has served as a Senior Advisor at Lazard and as a member of Lazard’s Life Sciences Group as a Managing Director. Mr. Low has advised on major mergers and acquisitions transactions in the life sciences, biotechnology and medical technology sectors, and has worked with private and public companies to raise capital, including emerging growth companies. Prior to joining Lazard, Mr. Low was a Managing Director at JP Morgan and a Senior Vice President at Lehman Brothers. Mr. Low also serves on the Regional Advisory Board of the Institute of International Education West Coast Center, on the Board of Directors for Lets Be Frank Dogs and on the Board of Directors of We Teach Science Foundation. Mr. Low holds an A.B. from Harvard College, where he graduated cum laude, an M.A. from the Johns Hopkins University School of Advanced International Studies and an M.B.A. from Yale University.

Michael Otto

Dr. Michael J. Otto, Ph.D. is a Independent Director of CONTRAFECT CORPORATION., Dr. Otto served as Chief Scientific Officer of Pharmasset, Inc. from October 1999 until February 2012, when the company was acquired by Gilead Sciences. While at Pharmasset, Dr. Otto led the research team responsible for the discovery of sofosbuvir, a drug used for the treatment of HCV infections. Earlier in his career, Dr. Otto served as Associate Director of Anti-Infectives Clinical Research at Rhône-Poulenc Rorer, Vice President for Research and Development at Avid Therapeutics, Inc., Research Manager at DuPont Pharmaceuticals and Dupont Merck Pharmaceuticals and as Group Leader in the Virology Department at Sterling Drug. Prior to joining Sterling Drug, Dr. Otto was Research Assistant Professor at the Yale University School of Medicine, Department of Pharmacology. Dr. Otto also served as the U.S. editor for Antiviral Chemistry & Chemotherapy, a peer-reviewed academic journal, from 1989 until 2012. Dr. Otto holds a B.S. from Loyola University of Chicago and a Ph.D. in medical microbiology from The Medical College of Wisconsin.

David Scheinberg

Dr. David A. Scheinberg is a Independent Director of CONTRAFECT CORPORA., Dr. Scheinberg has served as Vincent Astor Chair and Chairman of the Molecular Pharmacology and Chemistry Program at the Sloan-Kettering Institute. In 2002, he also founded and serves as the Chair of the Experimental Therapeutics Center at the Memorial Sloan-Kettering Cancer Center. Dr. Scheinberg has been a Professor of Medicine (since 2002) and Pharmacology (since 1999) at the Weill-Cornell University Medical College and has served as Co-chair of the Pharmacology graduate program since 2001. He has served as a Professor at the Gerstner-Sloan Kettering Graduate School at the Memorial Sloan-Kettering Cancer Center since 2005. From 1992 until 2003, he was Chief of the Leukemia Service at Memorial Hospital. He founded and is a Director of the Therapeutics Discovery Institute, a non-profit drug development corporation, which is a subsidiary of Rockefeller, Weill Cornell Medical College and Memorial Sloan-Kettering. He has been elected into the American Society of Clinical Investigation, the American Association of Physicians and the Interurban Club. His other awards include the Doris Duke Distinguished Clinical Science Professorship, the Lucille P. Markey Scholarship, Leukemia and Lymphoma Society Translational Investigator Awards, and CapCure Awards. He Co-chairs the Medical Board of the Laurie Strauss Leukemia Foundation. He was a founder and Chairman of the board of directors of Active Biotherapeutics, Inc., a private company that was acquired by Progenics Pharmaceuticals, and is currently a member of the Scientific Advisory Boards of Pfizer CTI, Oncopep and Encyse Pharma. Dr. Scheinberg received his A.B., cum laude, distinction in all subjects, from the College of Arts & Sciences, Cornell University, in 1977. He earned his M.D. from Johns Hopkins University in 1983, and his Ph.D. from Johns Hopkins University School of Medicine,

Cary Sucoff

Mr. Cary W. Sucoff is a Director of CONTRAFECT CORPORATION., Mr. Sucoff has over 30 years of securities industry experience encompassing supervisory, banking and sales responsibilities. Mr. Sucoff currently owns and operates Equity Source Partners, LLC, an advisory and consulting firm. Prior to December 2011, Equity Source Partners, LLC operated as a boutique investment bank. During that time, Mr. Sucoff provided investment banking and consulting services to public and private companies and institutional investors. Mr. Sucoff has played a role in financings for biotechnology companies such as Amgen Inc., Janssen Biotech, Inc. (formerly Centocor Biotech, Inc.), Genzyme Corporation, Genentech, Inc., ICOS Corporation (acquired by Eli Lilly and Company), PathoGenesis Corporation (acquired by Chiron Corp.), Vaxgen Inc. and BioTime, Inc. Mr. Sucoff currently serves on the boards of directors of Cerecor, Inc., Premier Alliance Group, Inc., and The SpendSmart Payments Corp. In addition, Mr. Sucoff serves as a consultant to Medgenics, Inc., and RestorGenex. Mr. Sucoff is the President of New England Law/Boston, has been a member of the Board of Trustees for over 25 years and is the current Chairman of the Endowment Committee. Mr. Sucoff received a B.A. from SUNY Binghamton (1974) and a J.D. from New England School of Law (1977) where he was the Managing Editor of the Law Review and graduated Magna Cum Laude. Mr. Sucoff has been a member of the Bar of the State of New York since 1978. The company believes that Mr. Sucoff’s broad financial and legal experience qualifies him to serve as a member of our board of directors.